Corcept Common Stock vs Capital Surpluse Analysis
CORT Stock | USD 51.40 0.25 0.49% |
Corcept Therapeutics financial indicator trend analysis is way more than just evaluating Corcept Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Corcept Therapeutics is a good investment. Please check the relationship between Corcept Therapeutics Common Stock and its Capital Surpluse accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Corcept Therapeutics Incorporated. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
Common Stock vs Capital Surpluse
Common Stock vs Capital Surpluse Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Corcept Therapeutics Common Stock account and Capital Surpluse. At this time, the significance of the direction appears to have strong relationship.
The correlation between Corcept Therapeutics' Common Stock and Capital Surpluse is 0.69. Overlapping area represents the amount of variation of Common Stock that can explain the historical movement of Capital Surpluse in the same time period over historical financial statements of Corcept Therapeutics Incorporated, assuming nothing else is changed. The correlation between historical values of Corcept Therapeutics' Common Stock and Capital Surpluse is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock of Corcept Therapeutics Incorporated are associated (or correlated) with its Capital Surpluse. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capital Surpluse has no effect on the direction of Common Stock i.e., Corcept Therapeutics' Common Stock and Capital Surpluse go up and down completely randomly.
Correlation Coefficient | 0.69 |
Relationship Direction | Positive |
Relationship Strength | Significant |
Common Stock
Capital Surpluse
Most indicators from Corcept Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Corcept Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Corcept Therapeutics Incorporated. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. Selling General Administrative is likely to gain to about 193.1 M in 2024. Tax Provision is likely to gain to about 19.3 M in 2024
2021 | 2022 | 2023 | 2024 (projected) | Other Operating Expenses | 241.5M | 289.2M | 375.1M | 393.8M | Research Development | 113.9M | 131.0M | 184.4M | 193.6M |
Corcept Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Corcept Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Corcept Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 412.3M | 571.7M | 423.8M | 583.4M | 621.5M | 652.6M | |
Other Current Liab | 30.1M | (11.5M) | 39.1M | 58.1M | 65.4M | 68.7M | |
Total Current Liabilities | 41.1M | 10.6M | 6.9M | 81.6M | 104.5M | 109.7M | |
Accounts Payable | 7.5M | 10.6M | 6.9M | 12.0M | 17.4M | 18.3M | |
Cash | 315.3M | 476.9M | 335.8M | 436.6M | 135.6M | 116.6M | |
Other Current Assets | 6.0M | 6.7M | 10.3M | 45.0M | 41.6M | 43.6M | |
Total Liab | 41.1M | 48.4M | 48.0M | 81.6M | 114.8M | 120.6M | |
Common Stock | 120K | 122K | 127K | 131K | 133K | 85.9K | |
Property Plant Equipment | 1.1M | 1.7M | 1.0M | 1.8M | 2.0M | 2.1M | |
Total Stockholder Equity | 371.2M | 523.3M | 375.8M | 501.8M | 506.7M | 532.0M | |
Other Assets | 61.1M | 52.9M | 43.5M | 77.5M | 89.1M | 93.5M | |
Common Stock Shares Outstanding | 122.6M | 124.2M | 126.0M | 116.0M | 111.7M | 83.1M | |
Liabilities And Stockholders Equity | 412.3M | 571.7M | 423.8M | 583.4M | 621.5M | 652.6M | |
Other Stockholder Equity | 394.4M | 440.3M | 180.9M | 206.2M | 103.4M | 98.3M | |
Short Term Investments | 244.7M | 364.5M | 145.9M | 365.3M | 232.7M | 244.3M | |
Property Plant And Equipment Net | 3.4M | 2.5M | 514K | 1.1M | 315K | 559.2K | |
Net Debt | (311.9M) | (474.3M) | (335.3M) | (435.5M) | (135.4M) | (142.2M) | |
Retained Earnings | (23.6M) | 82.5M | 195.0M | 296.4M | 402.5M | 422.7M | |
Non Current Assets Total | 59.7M | 47.5M | 42.4M | 84.7M | 162.9M | 171.0M | |
Non Currrent Assets Other | 10.5M | 13.4M | 14.4M | 17.2M | 14.8M | 15.5M | |
Cash And Short Term Investments | 315.3M | 476.9M | 335.8M | 436.6M | 368.2M | 386.6M | |
Common Stock Total Equity | 117K | 120K | 122K | 127K | 146.1K | 87.7K | |
Non Current Liabilities Total | 1.9M | 37.8M | 41.0M | 9.1M | 10.3M | 12.7M | |
Property Plant And Equipment Gross | 4.5M | 4.2M | 514K | 1.1M | 315K | 299.3K | |
Total Current Assets | 352.6M | 524.2M | 381.4M | 498.7M | 458.6M | 481.6M | |
Accumulated Other Comprehensive Income | 261K | 415K | (227K) | (869K) | 609K | 639.5K | |
Net Tangible Assets | 371.2M | 523.3M | 375.8M | 501.8M | 577.1M | 606.0M | |
Retained Earnings Total Equity | (117.7M) | (23.6M) | 82.5M | 195.0M | 224.2M | 235.4M | |
Capital Surpluse | 417.2M | 457.1M | 516.1M | 591.3M | 680.1M | 426.4M | |
Inventory | 17.4M | 21.2M | 18.0M | 17.0M | 7.7M | 9.6M | |
Net Receivables | 19.9M | 26.2M | 27.6M | 31.1M | 41.1M | 43.2M | |
Net Invested Capital | 371.2M | 523.3M | 375.8M | 501.8M | 506.7M | 431.5M | |
Long Term Investments | 39.4M | 36.2M | 112.3M | 4.9M | 57.2M | 41.7M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Corcept Stock Analysis
When running Corcept Therapeutics' price analysis, check to measure Corcept Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corcept Therapeutics is operating at the current time. Most of Corcept Therapeutics' value examination focuses on studying past and present price action to predict the probability of Corcept Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corcept Therapeutics' price. Additionally, you may evaluate how the addition of Corcept Therapeutics to your portfolios can decrease your overall portfolio volatility.